J.W. Cole Advisors Inc. Sells 13,668 Shares of Boston Scientific Corporation $BSX

J.W. Cole Advisors Inc. reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 61.5% in the third quarter, Holdings Channel reports. The institutional investor owned 8,566 shares of the medical equipment provider’s stock after selling 13,668 shares during the period. J.W. Cole Advisors Inc.’s holdings in Boston Scientific were worth $836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of BSX. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the third quarter worth about $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter worth about $26,000. United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Evercore lowered their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. National Bankshares set a $115.00 price objective on Boston Scientific in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada dropped their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $109.43.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 2.7%

Shares of BSX stock opened at $74.20 on Tuesday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $110.00 billion, a price-to-earnings ratio of 38.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $74.07 and a 12-month high of $109.50. The stock’s 50-day moving average price is $92.85 and its 200-day moving average price is $98.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.